Inactive Instrument

Precision Therapeutics Inc Stock Nasdaq

Equities

US74033P1003

Medical Equipment, Supplies & Distribution

Sales 2022 1.51M 2.07M Sales 2023 1.78M 2.45M Capitalization 13.37M 18.38M
Net income 2022 -25M -34.38M Net income 2023 -14M -19.25M EV / Sales 2022 1.5 x
Net cash position 2022 21.89M 30.1M Net cash position 2023 5.87M 8.07M EV / Sales 2023 4.21 x
P/E ratio 2022
-0.87 x
P/E ratio 2023
-0.94 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 96.48%
More Fundamentals * Assessed data
Dynamic Chart
Predictive Oncology Inc. Develops Novel Stem Cell Expression System for the Production of Functional and Stable G-Protein Coupled Receptors CI
Predictive Oncology Inc. Launches Novel 3D Cell Technology to Accelerate Cancer Therapeutic Drug Discovery CI
Top Premarket Gainers MT
Predictive Oncology Inc. Announces Positive Results from Ovarian Cancer Study with UPMC Magee-Womens Hospital to be Presented at the 2024 American Society of Clinical Oncology Annual Meeting CI
Transcript : Predictive Oncology Inc., Q1 2024 Earnings Call, May 15, 2024
Earnings Flash (POAI) PREDICTIVE ONCOLOGY Posts Q1 Revenue $419,646 MT
Predictive Oncology Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts MT
Investors Await Fed Rate Decision as US Futures Trend Lower in Wednesday's Premarket MT
Top Premarket Gainers MT
Predictive Oncology Inc. Announces Significant Progress with FluGen in Development of Intranasal Flu Vaccine CI
FUJIFILM Wako Chemicals U.S.A. Corporation and Predictive Oncology Announce Collaboration to Reduce Protein Interference in Bacterial Endotoxin Detection Testing of Biopharmaceuticals CI
Transcript : Predictive Oncology Inc., Q4 2023 Earnings Call, Apr 01, 2024
Predictive Oncology Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Predictive Oncology Inc. Announces Resignation of Pamela Bush, as Chief Business Officer, Effective from February 15, 2024 CI
More news
Predictive Oncology Inc. is a knowledge-driven company focused on applying artificial intelligence (AI) to support the development of cancer therapies. The Company operates through three segments: Pittsburgh, Birmingham, and Eagan. Pittsburgh segment provides services, which include the application of artificial intelligence (AI) using its proprietary biobank of 150,000 plus tumor samples. Pittsburgh segment also develops tumor-specific in vitro models for oncology drug discovery and research. Birmingham segment focuses on contract services and research for biopharmaceutical company clients and academic collaborators, focused on solubility improvements, stability studies, and protein production. Specifically, Birmingham provides optimized formulations for vaccines, antibodies, and other protein therapeutics. Eagan segment produces the STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal.
More about the company